CORT Key Stats
- 3 Pharmaceutical Stocks to Sell Now Investor Place May 10
- CORCEPT THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report May 8
- Wider-than-Expected Loss at Corcept May 7
- Corcept Therapeutics slips following downgrade May 6
- UPDATE: Piper Jaffray Downgrades Corcept Therapeutics to Neutral Following 1Q13 ... May 6
- Piper Jaffray Downgrades Corcept Therapeutics (CORT) to Neutral Street Insider May 6
- Corcept Therapeutics' CEO Discusses Q1 2013 Results - Earnings Call Transcript Seeking Alpha May 2
- Corcept Therapeutics Announces First Quarter 2013 Financial Results noodls May 2
- Corcept Therapeutics, Inc. (CORT) Posts Q1 loss of 10c/Share Street Insider May 2
- CORCEPT THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial... May 2
CORT Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Corcept Therapeutics is down 54.64% over the last year vs S&P 500 Total Return up 31.59%, Mast Therapeutics up 22.22%, and Cempra down 2.77%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for CORT
Pro Report PDF for CORT
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download CORT Pro Report PDF
Pro Strategies Featuring CORT
Did Corcept Therapeutics make it into our Pro Portfolio Strategies?